Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC
Status:
Completed
Trial end date:
2020-03-13
Target enrollment:
Participant gender:
Summary
Phase I dose escalating trial. Primary objective of this study is to define the maximal
tolerated dose (MTD)of Olaparib in combination with high dose radiotherapy with or without
daily dose Cisplatin in locally advanced NSCLC. Secondary objectives include to define safety
profile, determine PK/Pd variables and document preliminary evidence of objective tumor
response.